This might suggest that CRC patients with low expression of FGD5-AS1, FLG-AS1, and MIR31HG were related to the increase of sensitivity of the chemotherapy and weaker proliferation of tumor cells. This evidence concerns the gene FGD5 and colorectal carcinoma.